Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Hepatology. 2021 May 8;73(6):2342–2360. doi: 10.1002/hep.31614

Figure 8. Evaluation of Fibronectin as a non-invasive biomarker of HCC.

Figure 8

a. Clinical data for the case-control study to assess plasma biomarkers of vascular invasion. b. Plasma levels of FN1, AFP, VEGFR2 and PAI-1 in patients with HCC compared to cirrhosis-alone. c. ROC curves for the diagnosis of HCC of FN1, AFP, combined FN1+AFP, VEGFR2 and PAI-1. d. Correlation of plasma fibronectin levels with HCC tumor focality, tumor stage, etiology of cirrhosis and vascular invasion. * p<0.05; **p<0.01; ***p<0.001.